Portland Investment Counsel Inc. Buys $1.23M Stake in Telix Pharmaceuticals

Firm adds 128,000 shares of the clinical-stage biotech company to its portfolio

Mar. 14, 2026 at 9:21am

Got story updates? Submit your updates here. ›

Portland Investment Counsel Inc. has purchased a new position in Telix Pharmaceuticals Limited (NASDAQ:TLX), acquiring 128,000 shares of the clinical-stage biopharmaceutical company's stock valued at approximately $1.23 million. The investment represents about 0.3% of Portland Investment Counsel's portfolio.

Why it matters

Telix Pharmaceuticals is developing molecularly targeted radiopharmaceuticals for cancer diagnosis and treatment, an area of growing interest and investment in the biotech industry. Portland Investment Counsel's stake in the company signals confidence in Telix's pipeline and potential.

The details

According to a recent 13F filing, Portland Investment Counsel purchased the 128,000 shares of Telix Pharmaceuticals in the third quarter. The investment makes Telix the 28th largest holding in the firm's portfolio.

  • The shares were purchased during the third quarter of the year.
  • Telix Pharmaceuticals' stock is currently trading at around $7.85 per share.

The players

Portland Investment Counsel Inc.

An investment management firm based in Portland, Oregon that oversees a portfolio of stocks and other assets.

Telix Pharmaceuticals Limited

A clinical-stage biopharmaceutical company focused on the development and commercialization of molecularly targeted radiopharmaceuticals for cancer diagnosis and treatment.

Got photos? Submit your photos here. ›

The takeaway

Portland Investment Counsel's investment in Telix Pharmaceuticals reflects growing institutional interest in the company's cancer-focused radiopharmaceutical pipeline, which could signal positive momentum for the biotech firm as it advances its clinical programs.